Skip to main content
TORII PHARMACEUTICAL CO., LTD. logo

TORII PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4551 ISIN · JP3635800000 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2025-08-07 Regulatory Filings
Country JP Japan
Listing T 4551

About TORII PHARMACEUTICAL CO., LTD.

https://www.torii.co.jp/en/

Torii Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and marketing of prescription drugs. The company's primary focus is on therapeutic agents for renal diseases and hemodialysis, particularly for chronic kidney disease (CKD). Its portfolio also includes products for skin diseases, HIV, and allergies. Torii Pharmaceutical utilizes strategic partnerships and promotes medical products from its parent company, Japan Tobacco, to provide specialized pharmaceutical solutions.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim/semi-annual report. H1 134
2025-08-07 Japanese
半期報告書－第134期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Torii Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements (balance sheets, income statements, etc.) for the interim period ending June 30, 2025, and includes an audit review statement. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2025-08-07 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director on July 10, 2025. The primary purpose stated in Section 1 is to announce the resolution by the Board of Directors to convene an Extraordinary General Meeting (EGM) to approve a reverse stock split (株式併合) which is part of a larger transaction following a Tender Offer (公開買付け) that did not result in 100% acquisition. This structure—an official report detailing the necessity and mechanics of a corporate action (reverse stock split, fractional share treatment) following a failed tender offer—is characteristic of a mandatory disclosure filing in Japan related to corporate restructuring or takeovers. Since the document is a comprehensive report detailing the corporate action, its rationale, and the mechanics of fractional share treatment, it is a formal regulatory filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for mandatory, non-periodic, specific corporate action disclosures that don't fit the other specific types (like 10-K, ER, or DEF 14A). However, the content is highly specific to a corporate action following a tender offer, which often falls under general regulatory disclosure requirements. Since there is no specific code for 'Tender Offer Report' or 'Corporate Action Filing' other than the general 'RNS', and the document is a full report, not just an announcement of a report (ruling 2 does not apply as the document is long and detailed), RNS is the best fit as a catch-all for specific regulatory disclosures not covered elsewhere.
2025-07-10 Japanese
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document header explicitly states the filing type as "臨時報告書" (Extraordinary Report or Timely Disclosure Report) submitted to the "関東財務局長" (Director of the Kanto Local Finance Bureau) on June 19, 2025. The content details a change in major shareholders following a tender offer (公開買付け) by Shionogi & Co., Ltd., resulting in Shionogi acquiring 39.04% of the voting rights. This structure—a formal report detailing a significant event like a change in control or major shareholding following a tender offer—is characteristic of a major corporate event disclosure in Japan. Given the options, this is a specific regulatory filing concerning a change in ownership/control, which often falls under the scope of a Tender Offer/M&A activity (TAR) or a general Regulatory Filing (RNS). However, since the core event is the result of a tender offer leading to a major shareholder change, and the document is a formal report (not just an announcement of a report), it aligns closely with the context of M&A/Takeover Bids (TAR). If TAR is interpreted strictly as the bid document itself, then the closest fit for a post-bid change of control report is often a general Regulatory Filing (RNS) or, given the context of the tender offer mentioned, TAR is plausible. Since the document explicitly details the outcome of a '公開買付け' (Tender Offer), the 'M&A Activity (TAR)' category is the most specific fit for reporting the results of such an event, even though the Japanese term is '臨時報告書'. Given the definitions, TAR covers 'merger proposals or takeover bids'. This is the result of a takeover bid. I will classify it as TAR, as it is more specific than RNS.
2025-06-19 Japanese
訂正意見表明報告書
M&A Activity Classification · 100% confidence The document is titled '意見表明報告書' (Statement of Opinion Report) and is filed with the Kanto Local Finance Bureau ('関東財務局長'). The content details the target company's (Torii Pharmaceutical Co., Ltd.) opinion regarding a Tender Offer (公開買付け) proposed by Shionogi & Co., Ltd. This type of filing, where a target company states its position (support/oppose) on a tender offer, is specifically known in Japanese regulatory filings as a Statement of Opinion Report concerning a Tender Offer Bid, which corresponds to the US Schedule TO-I or Schedule 14D-9 equivalent, but within the provided schema, the closest fit for a document related to a takeover/merger proposal is 'M&A Activity' (TAR). The document explicitly discusses the '公開買付け' (Tender Offer) process, the scheme, pricing, and rationale for the acquisition, which falls under M&A activity.
2025-06-04 Japanese
意見表明報告書
M&A Activity Classification · 98% confidence The document is titled '意見表明報告書' (Statement of Opinion Report) and is submitted to the Kanto Local Finance Bureau Director. It explicitly discusses a '公開買付け' (Tender Offer) being made by Shionogi & Co., Ltd. for Torii Pharmaceutical Co., Ltd. The content details the tender offer price, the rationale for the offer (taking the company private), the two-step acquisition process involving a tender offer followed by a share consolidation and squeeze-out, and the target company's board resolution to support the offer. This structure and content are characteristic of a formal response document related to a Tender Offer Bid, which falls under the scope of takeover/merger activity disclosures. The closest matching category is 'M&A Activity' (TAR).
2025-05-08 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.